100s of titles, one news app for just $10 a month.
Dive Deeper:
Goldman Sachs Maintains Buy Rating for Cytek Biosciences: Here's What You Need To Know
Goldman Sachs has decided to maintain its Buy rating of Cytek Biosciences (NASDAQ:CTKB) and lower its price target from $14.00…
Needham Maintains Buy Rating for GLOBALFOUNDRIES: Here's What You Need To Know
Needham has decided to maintain its Buy rating of GLOBALFOUNDRIES (NASDAQ:GFS) and lower its price target from $87.00 to $70.00.…
Citigroup Maintains Buy Rating for Ultragenyx Pharmaceutical: Here's What You Need To Know
Citigroup has decided to maintain its Buy rating of Ultragenyx Pharmaceutical (NASDAQ:RARE) and lower its price target from $150.00 to…
B. Riley Securities Maintains Buy Rating for Ballard Power Systems: Here's What You Need To Know
B. Riley Securities has decided to maintain its Buy rating of Ballard Power Systems (NASDAQ:BLDP) and lower its price target…
One subscription that gives you access to news from hundreds of sites
Credit Suisse Maintains Neutral Rating for Groupon: Here's What You Need To Know
Credit Suisse has decided to maintain its Neutral rating of Groupon (NASDAQ:GRPN) and lower its price target from $29.00 to…
Deutsche Bank Maintains Buy Rating for Nomad Foods: Here's What You Need To Know
Deutsche Bank has decided to maintain its Buy rating of Nomad Foods (NYSE:NOMD) and raise its price target from $25.00…
Get all your news in one place
Latest Business news:
Musk: Twitter deal at lower price "not out of the question"
Musk has continued to express skepticism about the company's estimate of spam and fake accounts.
Read news from The Economist, FT, Bloomberg and more, with one subscription
Learn More
Netflix toys with live TV as sales slump
Would pouring more money into original content do anything to help Netflix's profits?
Michael 'Big Short' Burry Shorts Apple
Hedge fund investor Michael Burry bets against Apple.
Once a powerful symbol in Russia, McDonald's withdraws
Two months after the Berlin Wall fell, another powerful symbol opened its doors in the middle of Moscow: a gleaming…
U.S. backs U.N. push to get Ukraine grain back to global market
The United States supports efforts by U.N. Secretary-General Antonio Guterres to get Ukrainian grain back into the international marketplace amid…
From analysis to good news, read the world’s best news in one place
ASX rises despite economic worries, Wall Street struggles to recover from steep losses
Australian shares have started the day higher, despite another drop on Wall Street as investors weighed the potential for a…
Your Stocks, SPACs and Crypto Are Tumbling. Now What Do You Do?
Market experts offer their best suggestions for investors facing losses in popular – but sagging – asset classes.

Goldman Sachs Maintains Buy Rating for GoodRx Holdings: Here's What You Need To Know

By Benzinga Insights

Goldman Sachs has decided to maintain its Buy rating of GoodRx Holdings (NASDAQ:GDRX) and lower its price target from $30.00 to $12.00.

Shares of GoodRx Holdings are trading up 1.32% over the last 24 hours, at $8.07 per share.

A move to $12.00 would account for a 48.61% increase from the current share price.

About GoodRx Holdings

GoodRx is a consumer-focused digital healthcare platform that aims to lower the cost of healthcare in the United States. It has over 6 million active monthly users. The company's primary focus is the U.S. prescription drug market, where GoodRx has developed a price comparison tool that it aggregates from over 200 billion daily pricing data points, directing consumers toward coupons negotiated between a pharmacy and intermediaries (pharmacy benefit managers ). GoodRx generates revenue by taking a small share of the fees paid by pharmacies to PBMs in exchange for routing consumers to these discount programs, and separately through a subscription-based model (GoodRx Gold), which offers discounted drugs to customers paying a monthly membership fee.

About Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along with analyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

What is inkl?
The world’s most important news, from 100+ trusted global sources, in one place.
Morning Edition
Your daily
news overview

Morning Edition ensures you start your day well informed.

No paywalls, no clickbait, no ads
Enjoy beautiful reading

Content is only half the story. The world's best news experience is free from distraction: ad-free, clickbait-free, and beautifully designed.

Expert Curation
The news you need to know

Stories are ranked by proprietary algorithms based on importance and curated by real news journalists to ensure that you receive the most important stories as they break.

Dive Deeper:
Goldman Sachs Maintains Buy Rating for Cytek Biosciences: Here's What You Need To Know
Goldman Sachs has decided to maintain its Buy rating of Cytek Biosciences (NASDAQ:CTKB) and lower its price target from $14.00…
Needham Maintains Buy Rating for GLOBALFOUNDRIES: Here's What You Need To Know
Needham has decided to maintain its Buy rating of GLOBALFOUNDRIES (NASDAQ:GFS) and lower its price target from $87.00 to $70.00.…
Citigroup Maintains Buy Rating for Ultragenyx Pharmaceutical: Here's What You Need To Know
Citigroup has decided to maintain its Buy rating of Ultragenyx Pharmaceutical (NASDAQ:RARE) and lower its price target from $150.00 to…
B. Riley Securities Maintains Buy Rating for Ballard Power Systems: Here's What You Need To Know
B. Riley Securities has decided to maintain its Buy rating of Ballard Power Systems (NASDAQ:BLDP) and lower its price target…
One subscription that gives you access to news from hundreds of sites
Credit Suisse Maintains Neutral Rating for Groupon: Here's What You Need To Know
Credit Suisse has decided to maintain its Neutral rating of Groupon (NASDAQ:GRPN) and lower its price target from $29.00 to…
Deutsche Bank Maintains Buy Rating for Nomad Foods: Here's What You Need To Know
Deutsche Bank has decided to maintain its Buy rating of Nomad Foods (NYSE:NOMD) and raise its price target from $25.00…
Get all your news in one place